FLSM
AVDL

Frazier Life Sciences Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Frazier Life Sciences Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-951,814
Closed -$6.5M – 42
2022
Q1 		$6.5M Buy
+951,814
New +$6.54M 0.55% 34

Other funds holding AVDL

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Frazier Life Sciences Management's AVDL Position: Q2 2022 in Review

Frazier Life Sciences Management sold out of Avadel Pharmaceuticals (AVDL) in Q2 2022, closing a stake of 951,814 shares — an estimated $6.5M sold.

Frazier Life Sciences Management first reported a position in AVDL in Q1 2022 and held it in 1 quarter. The position peaked at $6.5M in Q1 2022. 82 funds tracked by Wall St. Rank hold AVDL as of Q2 2022.

  • Frazier Life Sciences Management reported no remaining Avadel Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Frazier Life Sciences Management sold 951,814 Avadel Pharmaceuticals shares in Q2 2022, an estimated $6.5M.
  • Frazier Life Sciences Management first reported a position in Avadel Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • Frazier Life Sciences Management's Avadel Pharmaceuticals position peaked at $6.5M in Q1 2022.
  • 82 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2022.

Based on Frazier Life Sciences Management's 13F filing for Q2 2022, filed 10 Aug 2022.